RM1NS138808
Project Grant
Overview
Grant Description
Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
In this COMBINE proposal the team seeks to develop an approach to facilitate the discovery of autoantibodies directed to cell surface antigens that may be directly pathogenic.
The specificity of these new autoantibodies will be deeply characterized and recombinant human monoclonal antibodies (MAbs) will be generated by single-cell sequencing.
These recombinant MAbs will allow the development of animal models of disease.
Tools to treat these new models in an antigen-specific manner will be pursued using novel approaches to identify neutralizing antibodies to target antibodies directly and by developing CAR-T cells, T cell-engagers (TCE), and NK-cell engagers (NKCEs) to target the autoantibody-producing B-cells.
The proposal describes the methodologies we’ve developed to pursue this goal and how we will develop new approaches.
We also describe as proof of principle a new autoantibody-dependent neuroinflammatory syndrome that will be the first target for this integrated approach.
In this COMBINE proposal the team seeks to develop an approach to facilitate the discovery of autoantibodies directed to cell surface antigens that may be directly pathogenic.
The specificity of these new autoantibodies will be deeply characterized and recombinant human monoclonal antibodies (MAbs) will be generated by single-cell sequencing.
These recombinant MAbs will allow the development of animal models of disease.
Tools to treat these new models in an antigen-specific manner will be pursued using novel approaches to identify neutralizing antibodies to target antibodies directly and by developing CAR-T cells, T cell-engagers (TCE), and NK-cell engagers (NKCEs) to target the autoantibody-producing B-cells.
The proposal describes the methodologies we’ve developed to pursue this goal and how we will develop new approaches.
We also describe as proof of principle a new autoantibody-dependent neuroinflammatory syndrome that will be the first target for this integrated approach.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Francisco,
California
94143
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 103% from $2,066,102 to $4,196,170.
San Francisco Regents Of The University Of California was awarded
Antigen-Directed Therapies Neuroinflammatory Diseases: A Novel Approach
Project Grant RM1NS138808
worth $4,196,170
from the National Institute of Neurological Disorders and Stroke in December 2024 with work to be completed primarily in San Francisco California United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
The Project Grant was awarded through grant opportunity Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 6/5/26
Period of Performance
12/15/24
Start Date
11/30/29
End Date
Funding Split
$4.2M
Federal Obligation
$0.0
Non-Federal Obligation
$4.2M
Total Obligated
Activity Timeline
Transaction History
Modifications to RM1NS138808
Additional Detail
Award ID FAIN
RM1NS138808
SAI Number
RM1NS138808-3310613504
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NQ00 NIH National Institute of Neurological Disorders and Stroke
Funding Office
75NQ00 NIH National Institute of Neurological Disorders and Stroke
Awardee UEI
KMH5K9V7S518
Awardee CAGE
4B560
Performance District
CA-11
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 6/5/26